

Lawrence R Dick

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5688392/publications.pdf>

Version: 2024-02-01

19
papers

4,387
citations

471509

17
h-index

794594

19
g-index

19
all docs

19
docs citations

19
times ranked

8473
citing authors

#	ARTICLE	IF	CITATIONS
1	An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer. <i>Nature</i> , 2009, 458, 732-736.	27.8	1,626
2	Potent and selective inhibitors of the proteasome: Dipeptidyl boronic acids. <i>Bioorganic and Medicinal Chemistry Letters</i> , 1998, 8, 333-338.	2.2	659
3	Ubiquitin-like protein conjugation and the ubiquitin-proteasome system as drug targets. <i>Nature Reviews Drug Discovery</i> , 2011, 10, 29-46.	46.4	456
4	Substrate-Assisted Inhibition of Ubiquitin-like Protein-Activating Enzymes: The NEDD8 E1 Inhibitor MLN4924 Forms a NEDD8-AMP Mimetic In Situ. <i>Molecular Cell</i> , 2010, 37, 102-111.	9.7	396
5	A small-molecule inhibitor of the ubiquitin activating enzyme for cancer treatment. <i>Nature Medicine</i> , 2018, 24, 186-193.	30.7	258
6	Artemisinin kills malaria parasites by damaging proteins and inhibiting the proteasome. <i>Nature Communications</i> , 2018, 9, 3801.	12.8	193
7	Probing the roles of SUMOylation in cancer cell biology by using a selective SAE inhibitor. <i>Nature Chemical Biology</i> , 2017, 13, 1164-1171.	8.0	163
8	Characterization of a new series of non-covalent proteasome inhibitors with exquisite potency and selectivity for the 20S β^5 -subunit. <i>Biochemical Journal</i> , 2010, 430, 461-476.	3.7	148
9	Treatment-Emergent Mutations in NAE1 Confer Resistance to the NEDD8-Activating Enzyme Inhibitor MLN4924. <i>Cancer Cell</i> , 2012, 21, 388-401.	16.8	98
10	Mechanistic Studies of Substrate-assisted Inhibition of Ubiquitin-activating Enzyme by Adenosine Sulfamate Analogues. <i>Journal of Biological Chemistry</i> , 2011, 286, 40867-40877.	3.4	78
11	Comparison of biochemical and biological effects of ML858 (salinosporamide A) and bortezomib. <i>Molecular Cancer Therapeutics</i> , 2006, 5, 3052-3061.	4.1	68
12	Target Validation and Identification of Novel Boronate Inhibitors of the <i>Plasmodium falciparum</i> Proteasome. <i>Journal of Medicinal Chemistry</i> , 2018, 61, 10053-10066.	6.4	54
13	Mechanistic Studies on Activation of Ubiquitin and Di-ubiquitin-like Protein, FAT10, by Ubiquitin-like Modifier Activating Enzyme 6, Uba6. <i>Journal of Biological Chemistry</i> , 2012, 287, 15512-15522.	3.4	38
14	Mechanistic Study of Uba5 Enzyme and the Ufm1 Conjugation Pathway. <i>Journal of Biological Chemistry</i> , 2014, 289, 22648-22658.	3.4	32
15	The proteasome as a target for protozoan parasites. <i>Expert Opinion on Therapeutic Targets</i> , 2019, 23, 903-914.	3.4	32
16	The structure of the PA28-20S proteasome complex from <i>Plasmodium falciparum</i> and implications for proteostasis. <i>Nature Microbiology</i> , 2019, 4, 1990-2000.	13.3	31
17	Reaction hijacking of tyrosine tRNA synthetase as a new whole-of-life-cycle antimalarial strategy. <i>Science</i> , 2022, 376, 1074-1079.	12.6	25
18	Design of proteasome inhibitors with oral efficacy in vivo against <i>Plasmodium falciparum</i> and selectivity over the human proteasome. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	7.1	19

#	ARTICLE	IF	CITATIONS
19	Absolute Quantification of E1, Ubiquitin-Like Proteins and Nedd8â€MLN4924 Adduct by Mass Spectrometry. Cell Biochemistry and Biophysics, 2013, 67, 139-147.	1.8	13